ZOE D. DANIIL, FRANCES C. GILCHRIST, ANDREW G. NICHOLSON, DAVID M. HANSELL, JESSICA HARRIS, THOMAS V. COLBY, and ROLAND M. du BOIS
|
|
- Nora McGee
- 5 years ago
- Views:
Transcription
1 A Histologic Pattern of Nonspecific Interstitial Pneumonia Is Associated with a Better Prognosis Than Usual Interstitial Pneumonia in Patients with Cryptogenic Fibrosing Alveolitis ZOE D. DANIIL, FRANCES C. GILCHRIST, ANDREW G. NICHOLSON, DAVID M. HANSELL, JESSICA HARRIS, THOMAS V. COLBY, and ROLAND M. du BOIS Interstitial Lung Disease Unit and Departments of Histopathology and Radiology, Royal Brompton Hospital, London, United Kingdom; and Department of Pathology, Mayo Clinic, Scottsdale, Arizona This study aimed to investigate whether there was a difference in outcome related to histologic pattern in cryptogenic fibrosing alveolitis (CFA) and to see whether there were correlations between clinical and radiologic findings and histology. One hundred thirteen lung biopsies from consecutive patients taken for the diagnosis of diffuse lung disease were reviewed and reclassified using the Katzenstein and Myers criteria for interstitial pneumonias. Patients lacking full investigational data at presentation and those with conditions predisposing to lung fibrosis were excluded, leaving 15 patients diagnosed with nonspecific interstitial pneumonia (NSIP) and 15 with usual interstitial pneumonia (UIP). Clinical and radiologic findings at presentation and serial lung function information and survival status in November 1998 were compared for the two groups. Survival was found to be significantly greater in the NSIP group compared with the UIP group (p 0.001). This could not be explained by differences in treatment. Patients with UIP showed a progressive deterioration in lung function whereas those with NSIP remained stable. CT scans of patients with UIP showed more fibrosis than those of patients with NSIP (p 0.011). A histologic diagnosis of NSIP is associated with a better prognosis than UIP. This subclassification of CFA is clinically useful. Daniil ZD, Gilchrist FC, Nicholson AG, Hansell DM, Harris J, Colby TV, du Bois RM. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. AM J RESPIR CRIT CARE MED 1999;160: (Received in original form March 1, 1999 and in revised form April 12, 1999) Correspondence and requests for reprints should be addressed to Dr. R. M. du Bois, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK. r.dubois@rbh.nthames.nhs.uk Am J Respir Crit Care Med Vol 160. pp , 1999 Internet address: Cryptogenic fibrosing alveolitis (CFA) is a chronically progressive interstitial lung disease characterized by poor prognosis and a limited response to treatment. The survival at 5 yr is approximately 50% and an objective response to corticosteroids is observed in only 20% of patients (1 5). Most patients diagnosed as having CFA, also termed idiopathic pulmonary fibrosis (IPF), show the features which fulfill the histopathologic criteria for usual interstitial pneumonia (UIP), the most common histologic type of idiopathic interstitial pneumonia (6, 7). Chronic interstitial pneumonias were originally classified by Liebow and Carrington into five groups: UIP, desquamative interstitial pneumonia (DIP), bronchiolitis obliterans with interstitial pneumonia (BIP), giant cell interstitial pneumonia (GIP), and lymphoid interstitial pneumonia (LIP) (8). Cases of BIP usually fall into the category now termed bronchiolitis obliterans organizing pneumonia (BOOP), and GIP is regarded as a pneumoconiosis associated with hard metal exposure. Furthermore, acute interstitial pneumonia (AIP) (9), nonspecific interstitial pneumonia (NSIP) (10), and respiratory bronchiolitis interstitial lung disease (RBILD) (11) have all been recently recognized. Their current interrelationships have been recently reviewed and a revised classification has been proposed by Katzenstein and Myers (6). The term NSIP has been proposed for cases that do not fit the histopathologic criteria for the other categories described above (10). NSIP is characterized by an interstitial inflammatory cell infiltrate with or without fibrosis and lacking the specific histologic features that characterize other forms of interstitial pneumonia. NSIP is most likely to be confused with UIP, but can be distinguished in most cases as NSIP does not show the temporal heterogeneity that is the cardinal feature of UIP. In NSIP the inflammation and fibrosis appear to be of a similar age, whether recent and active, or old and relatively quiescent. In UIP both processes are present but appear to be of different ages with a mixture of active inflammation and fibroblastic proliferation believed to reflect ongoing injury, and established fibrosis thought to reflect older injury and repair. Because of the wide range of survival in CFA we hypothesized that there may be differences in pathologic pattern between long-term survivors and those who succumb early. Lung biopsies taken for investigation of suspected CFA were reclassified using the Katzenstein and Myers criteria for idiopathic interstitial pneumonias (6). The results were correlated with
2 900 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL clinical, radiologic, and survival data with two aims: first, to confirm the findings of Katzenstein and Fiorelli (10), Bjoraker and coworkers (12), and Nagai and coworkers (13) that survival of patients diagnosed as having CFA or IPF is determined by the precise histopathologic subtype; and second, to relate the pathology to radiologic, in particular high-resolution computed tomography (HRCT), and clinical findings to determine whether there are distinguishing aspects of these histologic variants. METHODS Subject Selection Lung biopsies from the 113 consecutive patients who presented to the Royal Brompton Hospital between March 1990 and December 1995 for diagnosis of diffuse lung disease were reviewed. Open or thoracoscopic lung biopsies from all patients were independently reviewed by two pathologists (A.G.N. and T.V.C.) who were unaware of any clinical or physiologic findings. Histologic classification was based on previously published criteria for idiopathic interstitial pneumonias (6, 10). Cases in which there were different independent diagnoses were reevaluated by the two pathologists and a consensus diagnosis was agreed. Those with fibrosing alveolitis associated with connective tissue disease or environmental exposures known to cause fibrosing lung disease were excluded together with those categorized as having histopathologic diagnoses other than UIP or NSIP. This left 30 patients, 15 with the histologic features of NSIP and 15 with those of UIP. Clinical Information and Bronchoalveolar Lavage (BAL) Clinical data were obtained from patient medical records. Sex, age at presentation, onset of breathlessness, and smoking history were recorded. Subjects were classified as smokers if they had smoked at least one cigarette a day for more than 1 yr. Clinical histories were reviewed and those with any underlying medical condition or potential causes of pulmonary abnormalities (e.g., connective tissue disease, exposure to organic or inorganic dust or toxic fumes, and history of specific drug intake) were excluded. One patient in the UIP group had minor exposure to asbestos and hard metal and one patient in the NSIP group had been working as a thatcher (possible exposure to fungal spores) but fungal precipitins were negative. These two patients were included in the study group. Antinuclear antibodies (ANA), rheumatoid factor, and 99m Tc-DTPA clearance at presentation were recorded if available. ANA were measured by immunofluorescence. Samples were categorized subjectively into those negative for ANA and those weakly positive, moderately positive, and strongly positive. For the purposes of this study any degree of positivity was defined as positive. Rheumatoid factor titers were measured using the rapid particle agglutination test. A titer of greater than 1 in 160 was defined as a positive result. BAL had been performed for diagnostic or prognostic purposes in eight subjects in each group. HRCT Scans HRCT scans taken within 4 mo of biopsy were scored semiquantitatively by two observers. A global assessment was made using a fourpoint scale (0 no evidence of the particular pattern, through 3 pattern present throughout the abnormal lung) for the extent of the following HRCT patterns: honeycombing, interstitial thickening (fine reticular pattern), and traction bronchiectasis. A total fibrosis score (range, 0 to 9) was derived for each HRCT by adding the scores for each pattern. In addition, the HRCT scans were scored for the degree of lower zone predominance (0 no identifiable zonal distribution, through 3 lower zone predominant disease) and the subpleural predilection of the abnormalities (0 no obvious peripheral distribution, through 3 predominantly subpleural disease). A composite score to reflect disease distribution was derived for each case by totaling these two values (range, 0 to 6). The observers were also asked to categorize each HRCT scan as either typical of the published HRCT description of CFA or atypical for a diagnosis of CFA. Finally, HRCT scans were categorized into those which showed a uniform pattern of changes within 85% or more of the abnormal lung and those which showed a variable pattern. Pulmonary Function Tests In all cases lung function measurements were performed at presentation. Eleven patients in each group had carried out further lung function tests during the follow-up period. Tests included FEV 1, FVC, TLC, carbon monoxide diffusing capacity (DL CO ), and carbon monoxide diffusing capacity adjusted for alveolar volume (KCO). In some patients partial pressure of oxygen (Pa O2 ) in arterial blood was also measured. Results were expressed as percentages of values predicted from the subject s age, sex, and height (14). Throughout the study period, lung volumes were measured using an Ohio water-seal spirometer (Ohio Instruments, Atlanta, GA). TLC was measured in a wholebody plethysmograph (Fenyvens and Gut, Basel, Switzerland). Measures of gas transfer (DL CO, KCO) were made by the single-breath technique using a P.K. Morgan respirometer (P.K. Morgan, Chatham, Kent, UK). Criteria used to define significant changes in pulmonary function tests were identical to those used in previous studies (14, 15): improvement was defined as a rise of more than 15%, stability as a change of less than or equal to 15%, and deterioration as a decline of more than 15% from baseline values. Treatment Treatments used were identified from the medical records. Any effect of treatment on disease was assessed by comparison of lung function test results before and after diagnosis. Outcome Survival status in November 1998 was established either from hospital clinical records or from general practitioners records. Data Analysis Differences between subjects in the two groups (NSIP and UIP) were examined by the Mann-Whitney U test or chi-square test (for discrete variables). When patient numbers were small the chi-square test with Yates correction was used. Comparison of the frequency of improvement and deterioration in pulmonary function tests with treatment between the two histologically defined groups was made by the chisquare test. Comparison of the changes in pulmonary function tests during the follow-up period within each group was determined using the Wilcoxon matched pairs test. Survival was analyzed for those with UIP and NSIP and for those with typical and atypical appearances on HRCT. Survival curves were compared by the log rank test and Kaplan-Meier survival curves were plotted (16). RESULTS Pathologic Features In the 15 patients classified as having UIP there was independent agreement on diagnosis by both pathologists in all 15 cases. In the NSIP group, there was independent agreement in 10 cases. On reevaluation a consensus agreement on a diagnosis of NSIP was reached in five cases. Clinical Features All 30 patients had the clinical, radiologic, and physiologic criteria for the diagnosis of CFA. The NSIP group included seven men and eight women with a median age of 43 yr (range, 31 to 66 yr). The UIP group included 12 men and three women with a median age of 56 yr (range, 36 to 68 yr). Their clinical features are summarized in Table 1. No significant differences were found in age, sex, and smoking habits between the two groups. Functional indices of disease severity were similar in the two groups (Figure 1). The median duration of symptoms from onset to the first presentation to the unit were similar in the two groups: 18 mo (range, 7 to 84) in the NSIP group and 18 mo (range, 3 to 84) in the UIP group. Gradually increasing dyspnea and dry cough were the most common presenting symptom in both groups (Table 1). Chest pain was reported in two patients in the NSIP group and one in the UIP group. One patient in each group
3 Daniil, Gilchrist, Nicholson, et al.: Comparison of Histologic Subtypes in CFA 901 TABLE 1 DEMOGRAPHIC CHARACTERISTICS, CLINICAL FEATURES, AND INDICES OF LUNG FUNCTION AT PRESENTATION FOR ALL PATIENTS NSIP (n 15) UIP (n 15) p Value Age at presentation,* yr 43 (31 66) 56 (36 68) 0.21 Male 7 (47%) 12 (80%) 0.06 Ethnic origin 11 Caucasian 14 Caucasian 2 Indian 1 Indian 2 Afro-Caribbean Smoking, ever/never 9/6 12/ Presenting complaints Dyspnea Cough 9 9 Duration of symptoms before presentation, mo* 18.0 (7 84) 18.0 (3 84) 0.71 Crackles, n (%) 12 (80) 14 (93.3) 1.00 Clubbing, n (%) 6 (40) 14 (93.3) 0.01 FVC FEV TLC DL CO KCO PO 2, kpa* Definition of abbreviations: NSIP nonspecific interstitial pneumonia; UIP usual interstitial pneumonia. * Mean with standard deviation. Mean percentage of predicted value with standard deviation. complained of malaise. Wheezing was described by one patient in the NSIP group, and one patient in the UIP group had weight loss. One patient in the NSIP group had a history of possible viral pneumonia 7 mo before the open lung biopsy. Crackles were found in 12 patients (80%) in the NSIP group and in 14 patients (93%) in the UIP group. Digital clubbing occurred significantly more frequently in the UIP group in comparison with patients diagnosed as having NSIP (14/15 versus 6/15, p 0.01). Lung Function Pulmonary function tests at first presentation, including FEV 1, FVC, TLC, DL CO, KCO, and PO 2 were compared between the two groups. No significant difference was found in any of these indices (Table 1 and Figure 1). HRCT HRCT scans were available on 15 of 15 patients in the NSIP group and 12 of 15 in the UIP group. Results are shown in Table 2. The median time between HRCT and biopsy was 50 d in TABLE 2 RESULTS FOR SCORING OF HRCT SCANS FOR PATIENTS IN THE NSIP AND UIP GROUPS NSIP UIP p Value Number Median time between CT scan and biopsy, days (range) 50 (107 0) 56 (105 3) Fibrosis score,* median (range) 3.0 (0 7.0) 5.0 (2 7.0) Distribution score, median (range) 4 (0 6) 5 (1 6) Overal assessment Typical of CFA Atypical of CFA 13 4 Consistency of pattern Consistent Inconsistent 3 2 * Derived from the scores for honeycombing, traction bronchiectasis, and interstitial thickening. Derived from the scores for the degree of lower zone predominance and the predilection for a subpleural distribution. the NSIP group with a range of 107 to 0 d and 56 d in the UIP group with a range of 105 d before to 3 d after the biopsy. The fibrosis scores for the HRCTs in the two patient groups were compared. The median score in the NSIP group was found to be 3 (range, 0 to 7) compared with 5 (range, 2 to 7) in the UIP group (p 0.011). The HRCT scans were regarded as typical of CFA in two of 15 of the NSIP group, compared with eight of 12 in the UIP group (p 0.005). Only four HRCT scans in the UIP group were felt to be atypical for CFA compared with 13 in the NSIP group. Comparison of the scores reflecting distribution of the abnormalities seen on the HRCT scans failed to show a significant difference. In both groups the majority of scans were found to have consistency of pattern with only three in the NSIP group and two in the UIP group lacking homogeneity of the pattern of abnormal lung. DTPA Scan, ANA, and Rheumatoid Factor DTPA clearance was available in nine patients in the NSIP group and 10 in the UIP group. Clearance was abnormal in 10 of 10 patients with UIP and in seven of nine patients in the NSIP group (p 0.1). ANA was positive in five of the nine patients with NSIP in whom it had been checked compared with four of 13 in the UIP group (p 0.2). Rheumatoid factor was positive in two of 15 NSIP patients but negative in all the 13 UIP subjects in whom it had been checked (p 0.1). BAL BAL was performed at the first presentation in eight patients in each of the two groups. No significant differences were found on analysis of the lavage fluid in the proportions of lym- TABLE 3 BAL FLUID ANALYSIS IN PATIENTS WITH NSIP COMPARED WITH THOSE WITH UIP NSIP* UIP* p Value Figure 1. FVC and DL CO values at presentation in patients with UIP and NSIP. Horizontal bars indicate mean values in each group. Subjects 8 8 Macrophages, % Lymphocytes, % Neutrophils, % Eosinophils, % * Results are expressed as mean SD.
4 902 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL TABLE 4 EFFECTS OF TREATMENT ON LUNG FUNCTION IN PATIENTS WITH NSIP AND UIP NSIP (n 12) UIP (n 13) Improvement* 3 1 Stable 4 2 Deterioration 5 10 * Improvement a rise in FVC and/or DL CO of more than 15%. Unchanged no change or change of 15%. Deterioration a decline in FVC and/or DL CO of more than 15%. This category includes those who died during the first year of treatment (two in NSIP group and five in UIP group). phocytes, neutrophils, and macrophages in the two groups as a whole (Table 3). The numbers of patients in each group whose lavage fluid contained abnormal proportions of the different cell types were also comparable. Four patients in the NSIP group and five in the UIP group had above the normal range of eosinophils, one patient in each group had an abnormally high proportion of lymphocytes, and seven of eight in the UIP group and five of eight in the NSIP group had above the normal range of neutrophils in their lavage fluid. Effect of Treatment Of the 30 patients, 25 received treatment during the first year after biopsy, 12 in the NSIP group and 13 in the UIP group. Of the five patients untreated, two diagnosed as having UIP died shortly after presentation having been treated previously with both prednisolone and cyclophosphamide; two patients in the NSIP group had normal lung function and were not treated; one patient in the NSIP group was lost to follow-up immediately after lung biopsy. Seven patients, two in the NSIP group and five in the UIP group who were given treatment died within the first year after biopsy. Three of these failed to carry out further lung function tests after the diagnosis had been made. These are included in the assessment of response to treatment which is shown in Table 4. In the NSIP group, one patient received prednisolone only (60 mg daily for 6 wk, reducing over the next 9 wk to 15 mg TABLE 5 CHANGES IN LUNG FUNCTION BETWEEN PRESENTATION AND FINAL LUNG FUNCTION MEASUREMENT IN NSIP AND UIP PATIENTS NSIP (n 11) UIP (n 11) p Value Time from biopsy to final lung function assessment Median, mo Range, mo FVC change, mean SEM ml Percentage % % DL CO change, mean SEM mmol/min/kpa Percentage % % Dead 4 (29%) 13 (93%) Alive 10 (71%) 1 (7%) Total daily) and had an improvement in lung function tests. Eight patients received both prednisolone (20 mg on alternate days) and azathioprine (100 or 150 mg daily). Two died (one 4 mo and the other 6 mo after the initiation of the treatment), one patient improved, three remained stable, and the final two patients suffered a significant deterioration in lung function tests. Two patients in the NSIP group received prednisolone (20 mg on alternate days in combination with cyclophosphamide (150 mg and 100 mg daily). One deteriorated and the other remained stable. One patient in the NSIP group received cyclosporin (5 mg/kg/d) in combination with prednisolone (10 mg on alternate days) and improved. In the UIP group three patients received corticosteroids only (60 mg daily for 6 wk and reduced to 20 mg on alternate days). Two died 4 mo after the treatment had been started and the other showed significant deterioration in lung function. Three patients received both corticosteroids (two prednisolone 20 mg on alternate day and one prednisolone 20 mg daily) and azathioprine (150 mg daily). One improved, one remained stable, and one deteriorated. Six patients received corticosteroids (prednisolone 20 mg on alternate day in three Figure 2. Changes in DL CO between presentation and final lung function measurement in both groups.
5 Daniil, Gilchrist, Nicholson, et al.: Comparison of Histologic Subtypes in CFA 903 Figure 3. Changes in FVC between presentation and final lung function measurement in both groups. cases and 30 mg daily in two cases) in combination with cyclophosphamide (median dose 125 mg daily). Two died, one 4 mo and one 6 mo after the initiation of therapy, three deteriorated, and one remained stable. One patient in the UIP group was treated with -interferon and showed a decline in lung function. Overall seven of 12 patients (58%) with NSIP who were treated improved or remained stable on treatment compared with only three patients of 13 (23%) with UIP (p 0.03). Lung Function Changes during Follow-up to Last Visit or Death Eleven patients (73%) in each group performed lung function tests during follow-up after the diagnosis had been established by lung biopsy. The median duration of follow-up from the first to the final presentation to the unit was 14 mo (range, 3 to 72.5) in the NSIP group and 23.5 mo (range, 1.5 to 59) in the UIP group (Table 5). No significant changes were observed in either FVC where there was a mean improvement of % (mean SEM) or in DL CO (mean improvement of %) in the NSIP group as a whole. In contrast, patients diagnosed as having UIP showed a significant decline (p 0.03) in DL CO with a mean deterioration of % and in FVC (p 0.02) where there was a mean decline of % between presentation and final lung function measurements. Figures 2 and 3 show the changes seen in individual subjects. Three patients in the NSIP group showed a significant improvement in both FVC and DL CO during the follow-up period whereas DL CO improved significantly in a fourth with FVC remaining stable. Both indices were stable in four patients. Three patients suffered significant deterioration during the follow-up period, two in DL CO only and the third in both parameters. In the UIP group two patients improved significantly, two had stable lung function, and seven had a significant decline in pulmonary function tests, three in DL CO only and four in both DL CO and FVC. Taken as a group the patients with UIP had a significant loss in both FVC (p 0.03) and DL CO (p 0.05) compared with patients in the NSIP group. Survival status in November 1998 was ascertained for 14 patients in each group. In the NSIP group four patients (29%) died during the study period compared with 13 (93%) in the UIP group. This difference is significant (p 0.001). Survival from presentation was also significantly greater in the NSIP group compared with those diagnosed as having UIP (p 0.005) (Figure 4). Figure 5 compares survival in subjects according to the global assessment of their HRCT appearances at presentation. Survival and HRCT data were available on 10 subjects whose CT appearances were judged to be typical of CFA and in 14 whose CTs were felt to be atypical of a diagnosis of CFA. This shows that those with typical appearances have reduced survival compared with those with atypical appearances. The findings of this study are summarized diagramatically in Figure 6. This compares changes in FVC and DL CO and in survival during the study period in the two groups. DISCUSSION This study explored the clinical indices and outcome in a group of 30 patients who had been diagnosed as having CFA (IPF). The diagnosis had been made on the basis of clinical, radiographic, physiologic, and BAL features, coupled with a biopsy that was described at the time as being consistent with CFA. On review of the biopsy material, it was possible to subdivide this group of 30 individuals into those with an NSIP pattern and those with a UIP pattern (6, 10). This study showed Figure 4. Survival from presentation in both groups.
6 904 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL Figure 5. Comparison of survival in those with HRCT scans at presentation with the typical appearances of CFA (n 10) and those with scans atypical for CFA (n 14). that the response to therapy and survival was significantly better if a histopathologic pattern of NSIP was present as part of the CFA syndrome. The only clinical feature that showed a difference between the two groups was digital clubbing which was more frequent in the UIP group. However, we did find different patterns of abnormality on HRCT that increased the likelihood of predicting the pathologic subset preoperatively. Many studies have confirmed that the mean survival from time of diagnosis for CFA is 5 yr at most, but studies have also been consistent in demonstrating a tail on the survival curve (1 5, 17). It has long been suspected that this tail might represent a different disease subset or subsets. This study now provides evidence that would support this concept. Clinical outcome, radiology, and treatment response have all been quite different in the subset of individuals with CFA who have the NSIP pattern. The improved survival in patients with NSIP compared with those with UIP agrees with the findings of Katzenstein and Fiorelli in 1994 who assessed 64 cases of NSIP, and found Figure 6. Visual summary of the findings of this study. The first two pairs of columns comparing mean changes in FVC and DL CO during the study period in patients with NSIP and UIP. Positive values on the y-axis indicate improvement and negative values deterioration. The figure also provides a visual representation of survival in the two groups. The final two columns compare the percentage of patients who died in the two groups. In this case the y-axis indicates the proportion of patients in each group who died with a maximal value of 0% showing no deaths occurred to a minimum of 100% indicating the entire group died. an improved response to treatment and better prognosis when compared with UIP (10). These findings were supported by Bjoraker and coworkers in 1998 who studied 104 patients diagnosed as having IPF. These were reclassified on histological grounds into those with features of UIP, NSIP, and a group termed others. The 63 patients identified as having the UIP pattern showed reduced survival compared with both the 14 patients categorized into the NSIP group and the 20 who made up others (12). The Kyoto group studied 31 patients diagnosed as having NSIP and found their survival to be intermediate between those with UIP and those diagnosed with BOOP (13). The current study confirms the difference in survival determined by the histologic pattern and in addition has looked at radiologic and clinical correlations with histologic pattern showing that the difference in histology is reflected by different patterns on CT. We were surprised to find that, of our 30 patients with CFA, there were as many individuals with the NSIP as the UIP pattern. This suggests possible bias in selection. However, this is not the case. All patients who had surgical biopsies between the years 1991 and 1995 had their biopsies reviewed. From these, all patients with the UIP or NSIP pattern were selected. Those with clear etiologic factors or associated diseases such as systemic sclerosis, rheumatoid arthritis, or hypersensitivity pneumonitis were excluded. From the remaining patient group, only those who had full staging investigations at presentation were included. However, it remains surprising that there were so few patients with what we would regard as the more typical pattern of pathology, i.e., UIP. The reason for this is the use of HRCT. Since its introduction, we and others have reported that a coarse peripheral reticular pattern of disease on HRCT taken in the context of classic clinical features and investigation results predicts with a high degree of confidence, a diagnosis of fibrosing alveolitis (18 22). Thus, the selection of individuals for surgical biopsy has been restricted to those with some unusual features in their clinical, and particularly radiographic, workup. We suspect that classic cases of CFA with a UIP pattern are less likely than those with an NSIP pattern to have unusual features. HRCT was not absolute in being able to differentiate between these two pathologic processes. However, those with UIP tended to show more honeycombing and other signs of
7 Daniil, Gilchrist, Nicholson, et al.: Comparison of Histologic Subtypes in CFA 905 established fibrosis. In more subjective assessment, observers judged that only one of the HRCT scans from patients in the UIP group would have been regarded as atypical for CFA compared with eight in the NSIP group. Survival in those with typical appearances was found to be reduced compared with the other groups. This does therefore support the concept that HRCT can be of some help in distinguishing these groups, particularly in the more established honeycomb phase of the disease. This again is helpful in reducing the number of individuals who will require surgical confirmation of the diagnosis and will be particularly useful for individuals who have comorbid conditions making operative procedures more hazardous. This study has not been able to determine which treatment option is better for the different pathologic process. There are two reasons for this: first, the numbers in each group are too small and second, the spread of treatment options was very similar in the two groups. Answers to this question will require a prospective double-blind control study, stratified on the basis of pathologic subset to provide unequivocal rather than the current anecdotal evidence of treatment efficacy (10, 23, 24). With the exception of the HRCT pattern, no investigational index was helpful in differentiating the two histopathologic subsets. In particular, BAL showed a similar pattern of cellular return in the two groups. This is at variance with reports from the Kyoto group (13). Their studies have shown that BAL results in NSIP are similar to those seen in BOOP where there is an excess of lymphocytes. Our study did not confirm this. The reasons for this are unclear but could reflect ethnic or other differences in the population of patients studied. In summary, our study has shown that a diagnosis of CFA with an NSIP pattern carries a significantly better prognosis than a UIP pattern. This relates to response to treatment as well as survival. The only clinical feature that was different between the groups was the prevalence of digital clubbing. The only investigational difference was the pattern of HRCT abnormality. We conclude, therefore, that the pattern of histopathology is an important determinant in this disease and that we now have both noninvasive and histopathologic means of differentiating the two. Whether the NSIP variant requires change in the nomenclature from CFA must await further debate. Acknowledgment : The authors are grateful to Maria Bernardo for all her help in the preparation of this paper. References 1. Stack, B. H. R., Y. F. J. Choo-Kang, and B. E. Heard The prognosis of cryptogenic fibrosing alveolitis. Thorax 17: Turner-Warwick, M., B. Burrows, and A. Johnson Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 35: Carrington, C. B., E. A. Gaensler, R. E. Coutu, M. X. Fitzgerald, and R. G. Gupta Natural history and untreated course of usual and desquamative interstitial pneumonia. N. Engl. J. Med. 298: Tukiainen, P., E. Taskinen, P. Holsti, O. Korhola, and M. Valle Prognosis of cryptogenic fibrosing alveolitis. Thorax 38: Turner-Warwick, M., B. Burrows, and A. Johnson Cryptogenic fibrosing alveolitis: clinical features: response to corticosteroid treatment and its effect on survival. Thorax 35: Katzenstein, A. A., and J. L. Myers Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. J. Respir. Crit. Care Med. 157: Katzenstein, A. A Idiopathic interstitial pneumonia: classification and diagnosis. In IAP Monograph Series: Current Topics in Lung Pathology. Williams and Wilkins, Baltimore, MD Liebow, A. A., and C. B. Carrington The interstitial pneumonias. In M. Simon, E. J. Potchen, and E. Lemay, editors. Frontiers in Pulmonary Radiology. Grune and Stratton, New York Katzenstein, A. A., J. L. Myers, and M. T. Mazur Acute interstitial pneumonia: a clinicopathologic, ultrastructural, and cell kinetic study. Am. J. Surg. Pathol. 10: Katzenstein, A. A., and R. F. Fiorelli Nonspecific interstitial pneumonia/fibrosis: histologic features and clinical significance. Am. J. Surg. Pathol. 18: Myers, J. L., C. F. Veal, Jr., M. S. Shin, and A. A. Katzenstein Respiratory bronchiolitis causing interstitial lung disease: a clinicopathologic study of six cases. Am. Rev. Respir. Dis. 135: Bjoraker, J. A., J. H. Ryu, M. K. Edwin, J. L. Myers, H. D. Tazelaar, D. R. Schroeder, and K. P. Offord Prognostic significance of histological subsets in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 157: Nagai, S., M. Kitaichi, H. Itoh, T. Izumi, and T.V. Colby Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP. Eur. Respir. J. 12: Quanjer, P. H Standardised lung function testing. Clin. Respir. Physiol. 199(Suppl. 5): Chinet, T., D. Dusser, S. Labrune, M. A. Collignon, J. Chretien, and G. J. Huchon Lung function declines in patients with pulmonary sarcoidosis and increased respiratory epithelial permeability to 99mTc DTPA. Am. Rev. Respir. Dis. 141: Peto, R., M. C. Pike, P. Armitage, N. E. Breslow, D. R. Cox, S. V. Howard, N. Mantel, K. MacPherson, J. Peto, and P. G. Smith Design and analysis of randomised clinical trials requiring prolonged observation of each patient: analysis and examples. Br. J. Cancer 35: Agusti, C., A. Xaubet, J. Roca, A. Agusti, and R. Rodriguez-Roisin Interstitial pulmonary fibrosis with and without associated collagen vascular disease: results of a two year follow-up. Thorax 47: Tung, K. T., A. U. Wells, M. B. Rubens, J. M. E. Kirk, R. M. Du Bois, and D. M. Hansell Accuracy of the typical computed tomographic appearances of fibrosing alveolitis. Thorax 48: Wells, A. U., D. M. Hansell, M. B. Rubens, P. Cullinan, C. M. Black, and R. M. du Bois The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am. Rev. Respir. Dis. 148: Wells, A. U., M. B. Rubens, R. M. du Bois, and D. M. Hansell Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. Am. Respir. J. 161: Lee, J. S., J. Im, J. M. Ahn, Y. M. Kim, and M. C. Han Fibrosing alveolitis: prognostic implication of ground-glass attenuation at highresolution CT. Radiology 184: Terriff, B. A., S. Y. Kwan, M. M. Chan-Yeung, and N. L. Muller Fibrosing alveolitis: chest radiography and CT as predictors of clinical and functional impairment at follow-up in 26 patients. Radiology 184: Raghu, G., W. J. Depaso, K. Cain, S. P. Hammar, C. E. Wetzel, and D. F. Dreis Azathioprine combination with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis. 144: Johnson, M. A., S. Kwan, N. J. Snell, A. J. Nunn, J. H. Darbyshire, and M. Turner-Warwick Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 44:
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis JULIE A. BJORAKER, JAY H. RYU, MARK K. EDWIN, JEFFREY L. MYERS, HENRY D. TAZELAAR, DARRELL R. SCHROEDER, and KENNETH
More informationInternational consensus statement on idiopathic pulmonary fibrosis
Eur Respir J 2001; 17: 163 167 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 PERSPECTIVE International consensus statement on idiopathic
More informationANDREW G. NICHOLSON, THOMAS V. COLBY, ROLAND M. DUBOIS, DAVID M. HANSELL, and ATHOL U. WELLS
The Prognostic Significance of the Histologic Pattern of Interstitial Pneumonia in Patients Presenting with the Clinical Entity of Cryptogenic Fibrosing Alveolitis ANDREW G. NICHOLSON, THOMAS V. COLBY,
More informationDiffuse interstitial lung diseases (DILDs) are a heterogeneous group of non-neoplastic, noninfectious
Focused Issue of This Month Diagnostic Approaches to Diffuse Interstitial Lung Diseases Dong Soon Kim, MD Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine E -
More informationLiebow and Carrington's original classification of IIP
Liebow and Carrington's original classification of IIP-- 1969 Eric J. Stern MD University of Washington UIP Usual interstitial pneumonia DIP Desquamative interstitial pneumonia BIP Bronchiolitis obliterans
More informationCTD-related Lung Disease
13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of
More informationColchicine versus Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis A Randomized Prospective Study
Colchicine versus Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis A Randomized Prospective Study WILLIAM W. DOUGLAS, JAY H. RYU, STEPHEN J. SWENSEN, KENNETH P. OFFORD, DARRELL R. SCHROEDER,
More informationPrognosis of cryptogenic fibrosing alveolitis
P TUKIAINEN, E TASKINEN, P HOLSTI, 0 KORHOLA, AND M VALLE Thorax 1983;38:349-355 From the Departments of Pulmonary Diseases, Oncology, and Diagnostic Radiology, University Central Hospital ofhelsinki,
More informationCase Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco
Case Presentations in ILD Harold R. Collard, MD Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Definition/Classification High-resolution CT scan Multidisciplinary
More informationClinical significance of respiratory bronchiolitis on open lung biopsy and its relationship to smoking related interstitial lung disease
Thorax 1999;54:1009 1014 1009 James Moon, Ronald M du Bois, Thomas V Colby, David M Hansell, Andrew G Nicholson Interstitial Lung Disease Unit J Moon R M du Bois Department of Radiology D M Hansell Department
More informationKey words: CT scanners; interstitial lung diseases; polymyositis-dermatomyositis; x-ray
Nonspecific Interstitial Pneumonia Associated With Polymyositis and Dermatomyositis* Serial High-Resolution CT Findings and Functional Correlation Hiroaki Arakawa, MD; Hidehiro Yamada, MD; Yasuyuki Kurihara,
More information5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective No, I am not a pulmonologist! Radiology Pathology Clinical 1 Everyone needs a CT Confidence in diagnosis Definitive HRCT +
More information11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective Radiology Pathology Clinical 1 Role of HRCT Diagnosis Fibrosis vs. inflammation Next step in management Response to treatment
More informationOutline Definition of Terms: Lexicon. Traction Bronchiectasis
HRCT OF IDIOPATHIC INTERSTITIAL PNEUMONIAS Disclosures Genentech, Inc. Speakers Bureau Tadashi Allen, MD University of Minnesota Assistant Professor Diagnostic Radiology 10/29/2016 Outline Definition of
More informationSurvival in Patients With Cryptogenic Fibrosing Alveolitis*
Survival in Patients With Cryptogenic Fibrosing Alveolitis* A Population-Based Cohort Study Richard Hubbard, DM; Ian johnston, MD; and john Britton, MD Study objectives: To determine the median survival
More informationHistopathologic Subsets of Fibrosing Alveolitis in Patients with Systemic Sclerosis and Their Relationship to Outcome
Histopathologic Subsets of Fibrosing Alveolitis in Patients with Systemic Sclerosis and Their Relationship to Outcome Demosthenes Bouros, Athol U. Wells, Andrew G. Nicholson, Thomas V. Colby, Vlasis Polychronopoulos,
More informationSurvival of patients with biopsy-proven usual interstitial pneumonia and nonspecific interstitial pneumonia
Eur Respir J 2002; 19: 1114 1118 DOI: 10.1183/09031936.02.00244002 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Survival of patients with
More informationDiffuse Interstitial Lung Diseases: Is There Really Anything New?
: Is There Really Anything New? Sujal R. Desai, MBBS, MD ESTI SPEAKER SUNDAY Society of Thoracic Radiology San Antonio, Texas March 2014 Diffuse Interstitial Lung Disease The State of Play DILDs Is There
More informationBronchoalveolar lavage in fibrotic idiopathic interstitial pneumonias
Respiratory Medicine (2007) 101, 655 660 Bronchoalveolar lavage in fibrotic idiopathic interstitial pneumonias Yon Ju Ryu a, Man Pyo Chung b,, Joungho Han c, Tae Sung Kim d, Kyung Soo Lee d, Eun-Mi Chun
More informationNONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP
UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF () FOR PATHOLOGISTS Thomas V. Colby, M.D. Professor of Pathology (Emeritus) Mayo Clinic Arizona FINANCIAL DISCLOSURES NONE OVERVIEW IPF Radiologic Dx Pathologic
More informationDifferential diagnosis
Differential diagnosis Idiopathic pulmonary fibrosis (IPF) is part of a large family of idiopathic interstitial pneumonias (IIP), one of four subgroups of interstitial lung disease (ILD). Differential
More informationDIAGNOSTIC NOTE TEMPLATE
DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the
More informationNonspecific interstitial pneumonia and usual interstitial pneumonia: comparison of the clinicopathologic features and prognosis
Original Article Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparison of the clinicopathologic features and prognosis Xia Li 1, Chang Chen 2, Jinfu Xu 1, Jinming Liu 1, Xianghua
More informationA Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco
A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Why it is important Definition/Classification
More informationProgress in Idiopathic Pulmonary Fibrosis
Progress in Idiopathic Pulmonary Fibrosis David A. Lynch, MB Disclosures Progress in Idiopathic Pulmonary Fibrosis David A Lynch, MB Consultant: t Research support: Perceptive Imaging Boehringer Ingelheim
More informationFinancial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature
Financial disclosure I have no financial relationships to disclose. Douglas Johnson D.O. Cardiothoracic Imaging Gaston Radiology COMMON DIAGNOSES IN HRCT High Res Chest Anatomy Nomenclature HRCT Sampling
More informationCareful histopathological evaluation has shown the traditionally clinical diagnosis of
Demystifying Idiopathic Interstitial Pneumonia Harold R. Collard, MD; Talmadge E. King, Jr, MD REVIEW ARTICLE Careful histopathological evaluation has shown the traditionally clinical diagnosis of idiopathic
More information4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs
Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation
More informationA Review of Interstitial Lung Diseases
Outline A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Overview of diagnosis in ILD Why it is important Definition/Classification
More informationINTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018
INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial
More informationCase 4 History. 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar
Case 4 History 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar basilar infiltrates suggestive of pulmonary fibrosis Open
More informationIdiopathic Pulmonary Fibrosis: The Importance of Qualitative and Quantitative Phenotyping
Idiopathic Pulmonary Fibrosis: The Importance of Qualitative and Quantitative Phenotyping K. R. Flaherty Division of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor,
More informationTerminal Diffuse Alveolar Damage in Relation to Interstitial Pneumonias An Autopsy Study
Anatomic Pathology / DIFFUSE ALVEOLAR DAMAGE AS A TERMINAL EVENT Terminal Diffuse Alveolar Damage in Relation to Interstitial Pneumonias An Autopsy Study Alexandra J. Rice, MBBChir, 1 Athol U. Wells, MD,
More informationBronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy
Idiopathic Pulmonary Fibrosis Bronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy JMAJ 46(11): 469 474, 2003 Yukihiko SUGIYAMA Professor, Division of Pulmonary Medicine, Department of
More informationUsual Interstitial pneumonia and Nonspecific Interstitial Pneumonia. Nitra and the Gangs.
Usual Interstitial pneumonia and Nonspecific Interstitial Pneumonia Nitra and the Gangs. บทน ำและบทท ๓, ๑๐, ๑๒, ๑๓, ๑๔, ๑๕, ๑๗ Usual Interstitial Pneumonia (UIP) Most common & basic pathologic pattern
More informationUSEFULNESS OF HRCT IN DIAGNOSIS AND FOLLOW UP OF PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS
USEFULNESS OF HRCT IN DIAGNOSIS AND FOLLOW UP OF PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS Brestas P., Vergadis V., Emmanouil E., Malagari K. 2 nd Dept of Radiology, University of Athens, Greece ABSTRACT
More informationDisclosures. Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting. Relevant financial relationships: None. Off-label usage: None
Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona
More informationNon-neoplastic Lung Disease II
Pathobasic Non-neoplastic Lung Disease II Spasenija Savic Prince Pathology Program Systematic approach to surgical lung biopsies with ILD Examples (chronic ILD): Idiopathic interstitial pneumonias: UIP,
More informationCombined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases
CASE REPORT Combined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases Nobuhiko Nagata 1, Kentaro Watanabe 2, Michihiro Yoshimi 3, Hiroshi Okabayashi 4, Katsuo Sueishi 5, Kentaro
More informationJune 2013 Pulmonary Case of the Month: Diagnosis Makes a Difference. Lewis J. Wesselius, MD 1 Henry D. Tazelaar, MD 2
June 2013 Pulmonary Case of the Month: Diagnosis Makes a Difference Lewis J. Wesselius, MD 1 Henry D. Tazelaar, MD 2 Departments of Pulmonary Medicine 1 and Laboratory Medicine and Pathology 2 Mayo Clinic
More informationImaging: how to recognise idiopathic pulmonary fibrosis
REVIEW IDIOPATHIC PULMONARY FIBROSIS Imaging: how to recognise idiopathic pulmonary fibrosis Anand Devaraj Affiliations: Dept of Radiology, St George s Hospital, London, UK. Correspondence: Anand Devaraj,
More informationPulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment
Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,
More informationDiagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines
Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines Rebecca Keith, MD Assistant Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO Objectives
More informationIPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK?
IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? KEVIN K. BROWN, MD PROFESSOR AND VICE CHAIRMAN, DEPARTMENT OF MEDICINE NATIONAL JEWISH HEALTH DENVER, CO Kevin K.
More informationIdiopathic non-specific interstitial pneumonia: as an autoimmune interstitial pneumonia
Respiratory Medicine (2005) 99, 234 240 Idiopathic non-specific interstitial pneumonia: as an autoimmune interstitial pneumonia Jiro Fujita a,, Yuji Ohtsuki b, Takeo Yoshinouchi c, Ichiro Yamadori d, Shuji
More informationPatient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens
Patient with FVC>90% predicted Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 63-year-old, male patient with progressive exertional dyspnoea lasting for 2 years and dry cough
More informationUsual Interstitial Pneumonia and Non-Specific Interstitial Pneumonia: Serial Thin-Section CT Findings Correlated with Pulmonary Function
Usual Interstitial Pneumonia and Non-Specific Interstitial Pneumonia: Serial Thin-Section CT Findings Correlated with Pulmonary Function Yeon Joo Jeong, MD 1, 2 Kyung Soo Lee, MD 1 Nestor L. Muller, MD
More informationChanges in HRCT findings in patients with respiratory bronchiolitis-associated interstitial lung disease after smoking cessation
Eur Respir J 2007; 29: 453 461 DOI: 10.1183/09031936.00015506 CopyrightßERS Journals Ltd 2007 Changes in HRCT findings in patients with respiratory bronchiolitis-associated interstitial lung disease after
More informationUnpaid scientific collaborator & advisor with Veracyte, Inc.
Diagnosis and Classification of Idiopathic Interstitial Pneumonias: Role of Histopathology in the Golden Age of Consensus Jeffrey L. Myers, M.D. A. James French Professor of Diagnostic Pathology Vice Chair
More informationGuidelines for Diagnosis and Treatment of IPF
Guidelines for Diagnosis and Treatment of IPF Katerina Antoniou, MD, PhD Lecturer in Thoracic Medicine ERS ILD Group Secretary Medical School, University of Crete Classification of Interstitial Lung Disease
More informationEpidemiology and classification of smoking related interstitial lung diseases
Epidemiology and classification of smoking related interstitial lung diseases Šterclová M. Department of Respiratory Diseases, Thomayer Hospital, Prague, Czech Republic Supported by an IGA Grant No G 1207
More informationIn idiopathic pulmonary fibrosis (IPF) and
Eur Respir J 2010; 35: 830 835 DOI: 10.1183/09031936.00155108 CopyrightßERS Journals Ltd 2010 Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis
More informationFollicular bronchiolitis in surgical lung biopsies: Clinical implications in 12 patients
Respiratory Medicine (2008) 102, 307 312 Follicular bronchiolitis in surgical lung biopsies: Clinical implications in 12 patients Michelle R. Aerni a, Robert Vassallo a,, Jeffrey L. Myers b, Rebecca M.
More informationA case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel
A case of a patient with IPF treated with nintedanib Prof. Kreuter and Prof. Heussel Case Overview This case describes the history of a patient with IPF who, at the time of diagnosis, had symptoms typical
More informationThe radiological differential diagnosis of the UIP pattern
5th International Conference on Idiopathic Pulmonary Fibrosis, Modena, 2015, June 12th The radiological differential diagnosis of the UIP pattern Simon Walsh King s College Hospital Foundation Trust London,
More informationPatient with IPF and no honeycombing on HRCT. Case 1 Demosthenes Bouros, Vasilios Tzilas University of Athens
Patient with IPF and no honeycombing on HRCT Case 1 Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 76-year-old male patient presented with progressive exertional dyspnoea refractory
More informationLimitations of Corticosteroids and Cytotoxic Agents in Treating Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis Limitations of Corticosteroids and Cytotoxic Agents in Treating Idiopathic Pulmonary Fibrosis JMAJ 46(11): 475 482, 2003 Kingo CHIDA Associate Professor, Second Division,
More informationERS 2016 Congress Highlights Interstitial Lung Disease (ILD)
ERS 216 Congress Highlights Interstitial Lung Disease (ILD) London, UK September 3 rd 7 th 216 The 26 th European Respiratory Society International Congress, (ERS) the largest respiratory meeting in the
More informationTBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than
TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than PAP) BAL is not required as a diagnostic tool in patients
More informationThe Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page
The Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page 1135-1140 Role of High Resolution Computed Tomography in Diagnosis of Interstitial Lung Diseases in Patients with Collagen Diseases
More informationManish Powari Regional Training Day 10/12/2014
Manish Powari Regional Training Day 10/12/2014 Large number of different types of Interstitial Lung Disease (ILD). Most are very rare Most patients present with one of a smaller number of commoner diseases
More informationCOI: no conflicts of interest to declare
Idiopathic versus secondary Usual Interstitial Pneumonia (UIP) pattern in a series of 96 consecutive surgical lung biopsies: The value of histologic ancillary findings in a multidisciplinary discussion
More informationConnective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
More informationSmoking-related lung pathology represents a histologically
A Review of Smoking-Related Interstitial Fibrosis, Respiratory Bronchiolitis, and Desquamative Interstitial Pneumonia Overlapping Histology and Confusing Terminology Smoking-related lung diseases traverse
More informationR etrospective studies on the natural history of fibrosing
517 EXTENDED REPORT Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis J K Dawson, H E Fewins, J Desmond, M P Lynch, D R Graham... See end of article
More informationCriteria for confident HRCT diagnosis of usual interstitial pneumonia (UIP)
Criteria for confident HRCT diagnosis of usual interstitial pneumonia (UIP) Assem El Essawy (1) & Amr A. Nassef (٢) Abstract Identification of interstitial pneumonia (IP) was mainly based on histological
More informationSerial computed tomographic evaluation in desquamative interstitial pneumonia
Thorax 1997;52:333 337 333 Serial computed tomographic evaluation in desquamative interstitial pneumonia Masanori Akira, Satoru Yamamoto, Hideki Hara, Mitsunori Sakatani, Einosuke Ueda Abstract a better
More informationUpdate on Therapies for Idiopathic Pulmonary Fibrosis. Outline
Update on Therapies for Idiopathic Pulmonary Fibrosis Paul Wolters Associate Professor University of California, San Francisco Outline Classification of Interstitial lung disease Clinical classification
More informationI n 2002 the American Thoracic Society (ATS) and
1008 REVIEW SERIES Challenges in pulmonary fibrosis? 5: The NSIP/UIP debate Roland du Bois, Talmadge E King Jr... Among the idiopathic interstitial s, the two entities idiopathic pulmonary fibrosis (IPF)
More informationTreatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone Results of a Prospective, Open-label Phase II Study
Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone Results of a Prospective, Open-label Phase II Study GANESH RAGHU, W. CRAIG JOHNSON, DIANE LOCKHART, and YOLANDA MAGETO
More informationDiagnostic challenges in IPF
Medicine, Nursing and Health Sciences Diagnostic challenges in IPF Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University March 2015 Disclosures Consultancy fees from
More informationChallenges in the Diagnosis of Interstitial Lung Disease
Challenges in the Diagnosis of Interstitial Lung Disease Kirk D. Jones, MD UCSF Dept. of Pathology kirk.jones@ucsf.edu Overview New Classification of IIP Prior classification Modifications for new classification
More informationCryptogenic Organizing Pneumonia: Serial High-Resolution CT Findings in 22 Patients
Cardiopulmonary Imaging Original Research Lee et al. High-Resolution CT of Cryptogenic Organizing Pneumonia Cardiopulmonary Imaging Original Research Ju Won Lee 1 Kyung Soo Lee 1 Ho Yun Lee 1 Man Pyo Chung
More informationUNRAVELING THE ETIOLOGY OF FAMILIAL INTERSTITIAL PNEUMONIA: GENETIC INVESTIGATIONS OF A COMPLEX DISEASE. Anastasia Leigh Wise
UNRAVELING THE ETIOLOGY OF FAMILIAL INTERSTITIAL PNEUMONIA: GENETIC INVESTIGATIONS OF A COMPLEX DISEASE by Anastasia Leigh Wise University Program in Genetics and Genomics & Integrated Toxicology and Environmental
More informationDiagnosis of Respiratory Bronchiolitis associated interstitial lung disease
Monaldi Arch Chest Dis 2006; 65: 2, 96-101 ORIGINAL ARTICLE Diagnosis of Respiratory Bronchiolitis associated interstitial lung disease C. Robalo Cordeiro 1, S. Freitas 1, B. Rodrigues 1, A. Catarino 1,
More informationDisclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:
Disclosures Pharmacological Therapy for ILD What to Use and How to Use It Harold R Collard MD Interstitial Lung Disease Program University of California San Francisco (UCSF) I have relationships with the
More informationprednisolone in combination in cryptogenic fibrosing
Thorax 1989;44:280-288 Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis M A JOHNSON, S KWAN, N
More informationHRCT in Diffuse Interstitial Lung Disease Steps in High Resolution CT Diagnosis. Where are the lymphatics? Anatomic distribution
Steps in High Resolution CT Diagnosis Pattern of abnormality Distribution of disease Associated findings Clinical history Tomás Franquet MD What is the diagnosis? Hospital de Sant Pau. Barcelona Secondary
More informationAn earlier and more confident diagnosis of idiopathic pulmonary fibrosis
Eur Respir Rev 2012; 21: 124, 141 146 DOI: 10.1183/09059180.00000812 CopyrightßERS 2012 REVIEW: IPF An earlier and more confident diagnosis of idiopathic pulmonary fibrosis Roland M. du Bois ABSTRACT:
More informationT he diagnostic evaluation of a patient with
546 REVIEW SERIES Challenges in pulmonary fibrosis? 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias Michael B Gotway, Michelle M
More informationControversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF)
Controversies in Clinical Trials Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF) Controversies to be highlighted by IPF Post-hoc analyses Story Primary end point selection Changing prespecified endpoints
More informationReplacement of air with fluid, inflammatory. cells or cellular debris. Parenchymal, Interstitial (Restrictive) and Vascular Diseases.
Parenchymal, Interstitial (Restrictive) and Vascular Diseases Alain C. Borczuk, M.D. Dept of Pathology Replacement of air with fluid, inflammatory cells Pulmonary Edema Pneumonia Hemorrhage Diffuse alveolar
More informationDefinition, classification and epidemiology
Interstitial Lung Diseases Definition, classification and epidemiology Haluk Türktaş Professor of Pulmonary Medicine Gazi University Ankara Interstitial Lung Diseases Definition of ILD A diverse group
More informationDIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY?
NIHR Southampton Respiratory Biomedical Research Unit DIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY? Fibrosing Interstitial Lung Diseases CPFS/WASOG/AIPO/ERS
More informationPathologic Assessment of Interstitial Lung Disease
Pathologic Assessment of Interstitial Lung Disease Dry and itchy? It could be eczema or fungal infection. We don t need to worry, the drugs aren t that dangerous. Kirk D. Jones, MD UCSF Dept. of Pathology
More informationLines and crackles. Making sense of ILD
Lines and crackles Making sense of ILD Case JM 65 year old male Gradual shortness of breath, going on over a year Some dry cough Ex-smoker, quit 10 years ago Crackles in the bases CXR presented Sent to
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Idiopathic Pulmonary Fibrosis Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Idiopathic Pulmonary Fibrosis (Esbriet /pirfenidone, Ofev /nintedanib)
More informationThoracic lung involvement in rheumatoid arthritis: Findings on HRCT
Thoracic lung involvement in rheumatoid arthritis: Findings on HRCT Poster No.: C-2488 Congress: ECR 2015 Type: Educational Exhibit Authors: R. E. Correa Soto, M. J. Martín Sánchez, J. M. Fernandez 1 1
More informationUIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION!
UIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION! STÉPHANE JOUNEAU 11 JULY 2014 Respiratory Medicine Department, Pontchaillou Hospital, Rennes, France CASE OVERVIEW This case highlights how a usual
More informationInitial presentation of idiopathic pulmonary fibrosis as an acute exacerbation
Respiratory Medicine CME (2008) 1, 43 47 respiratory MEDICINE CME CASE REPORT Initial presentation of idiopathic pulmonary fibrosis as an acute exacerbation Krishna M. Sundar a,b,, Dixie L. Harris a a
More informationIPF: Epidemiologia e stato dell arte
IPF: Epidemiologia e stato dell arte Clinical Classification Diffuse parenchimal lung diseases Exposure-related: - occupational - environmental - medication Desquamative interstitial pneumonia Idiopathic
More informationA 72-year-old male with worsening interstitial infiltrates and respiratory failure
A 72-year-old male with worsening interstitial infiltrates and respiratory failure Case report On November 24, 2004, a 72-year-old male was admitted to the medical intensive care unit (ICU) with a history
More informationUsual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease
Eur Respir J 2010; 35: 1322 1328 DOI: 10.1183/09031936.00092309 CopyrightßERS 2010 Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease E.J. Kim*, B.M. Elicker #, F.
More informationConflicts of Interest. Advisory Board: Boehringer-Ingleheim, Genentech/Roche DSMB: Bristol-Myers Squibb, Fibrogen Clinical Endpoint Committee; Merck
Conflicts of Interest Advisory Board: Boehringer-Ingleheim, Genentech/Roche DSMB: Bristol-Myers Squibb, Fibrogen Clinical Endpoint Committee; Merck The Idiopathic Interstitial Pneumonias Idiopathic pulmonary
More informationOverview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy
Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Jeff Swigris, DO, MS Director, ILD Program National Jewish Health Disclosures Speaker - Boehringer Ingelheim and Genentech Objectives Describe
More informationHypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas
Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas Rishi Raj MD Director, Interstitial Lung Diseases Program Clinical Professor of Pulmonary and Critical Care Medicine Stanford University
More informationCLEARING THE AIR ON DIFFUSE PARENCHYMAL (INTERSTITIAL) LUNG DISEASE (ILD)
CLEARING THE AIR ON DIFFUSE PARENCHYMAL (INTERSTITIAL) LUNG DISEASE (ILD) David Northrop MBA, RRT Assistant Director of Respiratory Therapy Services The University of Kansas Health System Clinical Assistant
More informationH ypersensitivity pneumonitis (HP) comprises a group of
665 INTERSTITIAL LUNG DISEASE Chronic bird fancier s lung: histopathological and clinical correlation. An application of the 2002 ATS/ERS consensus classification of the idiopathic interstitial pneumonias
More informationIn medicine, the term overlap is very common, to the extent that there is even a
Case Report Payam Mehrian (MD) 1 Ali Cheraghvandi (MD) 2 Atousa Droudnia (PhD) 3 Firouzeh Talischi (MD) 4 Saeid Fallah Tafti (MD) *5 Shahram Kahkouee (MD) 6 Hamidreza Jamaati (MD) 7 1. Pediatric Respiratory
More information